Anti-CD19 CAR T-Cell (CNCT19) Infusion Following HDT/ASCT Is Safe and Effective in Patients with Relapsed/Refractory Large B-Cell Lymphoma

被引：0
|
作者：
Liu, Wei
Huang, Wenyang
Lv, Ryu
Deng, Shuhui
Yi, Shuhua
Liu, Huimin
Lv, Lulu
Qiu, Lugui
Zou, Dehui
Wang, Jianxiang
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-139351
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Anti-CD19 CAR T Therapy Following Autologous HSCT May be Safe and Effective in Patients with Refractory Large B-Cell Lymphoma
    Liu, Wei
    Huang, Wenyang
    Lv, Rui
    Deng, Shuhui
    Yi, Shuhua
    Qiu, Lugui
    Zou, Dehui
    BLOOD, 2019, 134
  • [2] Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma
    Chow, Victor A.
    Shadman, Mazyar
    Gopal, Ajay K.
    BLOOD, 2018, 132 (08) : 777 - 781
  • [3] CNCT19 CAR T-Cell Therapy in Relapsed or Refractory B-Cell Lymphoma: Long-Term Results of a Pilot Prospective Clinical Study
    Liu, Wei
    Huang, Wenyang
    Lv, Rui
    Liu, Huimin
    Yi, Shuhua
    Liu, Hong
    Lv, Lulu
    Qiu, Lugui
    Wang, Jianxiang
    Zou, Dehui
    BLOOD, 2022, 140 : 4598 - 4599
  • [4] Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
    Cordeiro, Ana Costa
    Durisek, George
    Batista, Marjorie Vieira
    Schmidt, Jayr
    de Lima, Marcos
    Bezerra, Evandro
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [5] Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study
    Tun, Aung M.
    Patel, Romil D.
    St-Pierre, Frederique
    Ouchveridze, Evguenia
    Niu, Alex
    Thordardottir, Thorunn
    Obasi, Jennifer
    Rosenthal, Allison
    Pophali, Priyanka A.
    Fenske, Timothy S.
    Karmali, Reem
    Ahmed, Sairah
    Johnston, Patrick B.
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (09) : 1712 - 1720
  • [6] Efficacy and side effects of anti-CD19 CAR T-cell therapy in patients with relapsed/refractory gastrointestinal lymphoma
    Jiang, Yi Li
    Mu, Juan
    Cui, Rui
    Li, Xin
    Wang, Jia
    Li, Qing
    Li, Jingyi
    Mou, Nan
    Deng, Qi
    CANCER MEDICINE, 2024, 13 (04):
  • [7] Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma
    Liu, Wei
    Zou, Hesong
    Chen, Lianting
    Huang, Wenyang
    Lv, Rui
    Xu, Yan
    Liu, Huimin
    Shi, Yin
    Wang, Kefei
    Wang, Yi
    Xiong, Wenjie
    Deng, Shuhui
    Yi, Shuhua
    Sui, Weiwei
    Peng, Guangxin
    Ma, Yueshen
    Wang, Huijun
    Lv, Lulu
    Wang, Jianxiang
    Wei, Jun
    Qiu, Lugui
    Zheng, Wenting
    Zou, Dehui
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (04)
  • [8] Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma
    Abramson, Jeremy S.
    TRANSFUSION MEDICINE REVIEWS, 2020, 34 (01) : 29 - 33
  • [9] Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed/refractory diffuse large B-cell lymphoma
    Sharon, T. Dubnikov
    Assayag, M.
    Avni, B.
    Kfir-Erenfeld, S.
    Lebel, E.
    Gatt, M. E.
    Goldschmidt, N.
    Stepensky, P.
    Asherie, N.
    Grisariu, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 202 (01) : 74 - 85
  • [10] Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma
    Saini, Neeraj
    Chang, Chia-Chi
    Strati, Paolo
    Nastoupil, Loretta J.
    Westin, Jason
    Nair, Ranjit
    Fayad, Luis
    Ahmed, Sairah
    Lee, Hun Ju
    Iyer, Swaminathan P.
    Steiner, Raphael Eric
    Greenbaum, Uri
    Kebriaei, Partow
    Shpall, Elizabeth J.
    Jain, Nitin
    Green, Michael R.
    Ajami, Nadim J.
    Flowers, Christopher
    Champlin, Richard E.
    Wargo, Jennifer
    Neelapu, Sattva S.
    Jenq, Robert R.
    BLOOD, 2020, 136
12345